Bicara therapeutics inc BCAX.US 總覽分析
BCAX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
BCAX 近期報酬表現
-1.43%
Bicara therapeutics inc
3.56%
同產業平均
1.47%
S&P500
與 BCAX 同產業的標的表現
- DNTH Dianthus therapeutics inc價值 2 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
BCAX 公司資訊
Bicara Therapeutics Inc. Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.